American Samoa
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.38 (4.45 - 6.28) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 6 (4.96 - 7.06) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.05 (4.91 - 7.32) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.11 (5.02 - 7.18) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.02 - 7.27) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.06 - 7.29) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.07 - 7.23) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.09 - 7.25) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.07 - 7.25) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.19 (5 - 7.32) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.21 (5.01 - 7.34) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.25 (4.98 - 7.39) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.29 (4.98 - 7.48) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.33 (4.98 - 7.55) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.34 (4.99 - 7.63) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.31 (5.02 - 7.56) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.25 (5.03 - 7.41) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.03 - 7.28) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.12 (5.02 - 7.20) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.09 (5 - 7.19) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.12 (5.04 - 7.26) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.2 (5.07 - 7.43) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.3 (5.10 - 7.64) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.38 (5.13 - 7.83) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.41 (5.10 - 7.97) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.4 (5.11 - 7.90) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.39 (5.11 - 7.89) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.37 (5.10 - 7.79) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.35 (5.09 - 7.71) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.31 (5.07 - 7.61) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.89 (4.90 - 6.85) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.2 | 2011 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
| 2.57 (1.80 - 3.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.23 (2.26 - 4.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.19 - 4.21) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.17 - 4.30) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.25 (2.22 - 4.33) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.3 (2.27 - 4.60) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.29 (2.25 - 4.57) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.25 (2.23 - 4.50) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.21 - 4.45) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.18 (2.19 - 4.39) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.18 (2.18 - 4.41) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.20 - 4.39) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.27 (2.25 - 4.46) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.34 (2.30 - 4.53) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.4 (2.34 - 4.62) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.43 (2.36 - 4.67) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.44 (2.36 - 4.64) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.42 (2.34 - 4.62) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.4 (2.31 - 4.59) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.39 (2.29 - 4.58) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.38 (2.27 - 4.61) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.4 (2.29 - 4.61) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.43 (2.28 - 4.63) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.47 (2.27 - 4.64) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.5 (2.26 - 4.69) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.52 (2.23 - 4.75) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.52 (2.26 - 4.77) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.53 (2.31 - 4.80) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.53 (2.33 - 4.84) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.52 (2.37 - 4.89) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.52 (2.37 - 4.92) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2,985 (2,472 - 3,484) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3,100 (2,579 - 3,608) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,157 (2,596 - 3,705) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,187 (2,587 - 3,857) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,224 (2,652 - 3,788) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,265 (2,653 - 3,854) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,272 (2,680 - 3,844) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,278 (2,691 - 3,844) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,287 (2,702 - 3,851) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,299 (2,703 - 3,850) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,315 (2,678 - 3,912) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,343 (2,692 - 3,929) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,380 (2,702 - 3,994) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,418 (2,705 - 4,066) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,450 (2,728 - 4,117) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,468 (2,726 - 4,174) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,463 (2,762 - 4,138) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,438 (2,764 - 4,073) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,403 (2,767 - 4,011) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,367 (2,771 - 3,968) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,340 (2,739 - 3,937) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,336 (2,746 - 3,948) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,351 (2,739 - 4,011) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,365 (2,723 - 4,078) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,360 (2,693 - 4,129) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,319 (2,637 - 4,123) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,248 (2,587 - 4,016) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,166 (2,531 - 3,890) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,073 (2,466 - 3,763) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,968 (2,382 - 3,610) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,851 (2,293 - 3,434) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 8.49 (6.81 - 10.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5.48 (4.44 - 6.60) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.45 (4.42 - 6.57) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.42 (4.46 - 6.49) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.39 (4.44 - 6.44) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.42 (4.46 - 6.46) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.42 (4.49 - 6.50) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.44 (4.49 - 6.53) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.45 (4.52 - 6.52) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.75 (4.75 - 6.95) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.02 (4.94 - 7.25) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.03 (4.99 - 7.26) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.97 (4.94 - 7.17) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.18 (5.17 - 7.40) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.03 (5.04 - 7.26) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.22 (5.18 - 7.50) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.3 (5.28 - 7.52) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.51 (5.47 - 7.72) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.62 (5.57 - 7.88) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.82 (5.76 - 8.09) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7 (5.87 - 8.28) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.18 (6.05 - 8.50) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.42 (6.26 - 8.80) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.87 (6.48 - 9.55) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.58 (6.30 - 9.05) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.75 (6.45 - 9.28) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.95 (6.47 - 9.69) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.12 (6.60 - 10.02) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.37 (6.70 - 10.45) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.25 (6.57 - 10.24) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.49 (6.81 - 10.68) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.31 (0.25 - 0.38) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.24 - 0.37) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.37) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.25 - 0.38) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.3 (0.24 - 0.36) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.22 - 0.33) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.24 (0.20 - 0.29) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.18 - 0.26) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.2 (0.17 - 0.24) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.21 (0.17 - 0.25) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.23 (0.19 - 0.28) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.26 (0.21 - 0.31) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.28 (0.23 - 0.34) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.3 (0.24 - 0.37) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.26 - 0.38) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.27 - 0.40) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.35 (0.29 - 0.42) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.30 - 0.44) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.32 - 0.45) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.29 (0.23 - 0.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 172 (143 - 204) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 171 (142 - 204) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 169 (138 - 202) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 166 (135 - 200) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 162 (131 - 195) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 157 (126 - 191) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 148 (121 - 181) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 137 (112 - 165) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 125 (102 - 150) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (95 - 138) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (92 - 134) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (92 - 134) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (93 - 134) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (93 - 134) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (92 - 134) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (92 - 134) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (96 - 141) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131 (107 - 157) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 147 (120 - 177) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 160 (130 - 195) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 166 (133 - 203) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 165 (134 - 203) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 164 (133 - 201) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 163 (132 - 199) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 162 (131 - 199) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 161 (130 - 198) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 161 (131 - 198) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 162 (130 - 199) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 162 (131 - 199) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 160 (128 - 200) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 162 (132 - 202) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.79 (2.83 - 4.93) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.71 (2.06 - 3.51) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.7 (2.05 - 3.47) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.68 (2.04 - 3.47) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.66 (2.03 - 3.44) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.67 (2.04 - 3.47) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.67 (2.06 - 3.46) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.8 (2.17 - 3.58) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.66 (2.07 - 3.43) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.68 (2.08 - 3.47) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.9 (2.24 - 3.70) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.87 (2.22 - 3.65) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.82 (2.18 - 3.59) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (2.19 - 3.63) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.88 (2.24 - 3.70) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.89 (2.25 - 3.68) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.91 (2.27 - 3.71) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3 (2.34 - 3.79) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.05 (2.38 - 3.83) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.13 (2.45 - 3.91) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.27 (2.56 - 4.09) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.2 (2.52 - 3.99) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.37 (2.62 - 4.21) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.45 (2.67 - 4.33) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.54 (2.71 - 4.50) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.5 (2.70 - 4.44) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.55 (2.70 - 4.55) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.6 (2.74 - 4.63) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (2.75 - 4.73) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.72 (2.80 - 4.81) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.79 (2.83 - 4.93) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
5
2019
(4 - 6)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
2
2019
(2 - 3)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines